AZD-9833 is a novel, highly potent and orally bioavailable SERD (Selective Estrogen Receptor Degrader) and ER Antagonist. AZD-9833 is used for the study of ER+ HER2-advanced breast cancer. AZD-9833 was demonstrated to be a highly potent SERD that showed a pharmacological profile comparable to fulvestrant in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines. A stringent control of lipophilicity ensured that AZD-9833 had favorable physicochemical and preclinical pharmacokinetic properties for oral administration.

纯度：≥98%

CAS：2222844-89-3